Keyphrases
Action Program
8%
Adjuvant Chemotherapy
6%
American Women
8%
Ancestry-specific
8%
Anthracyclines
8%
Brain Metastases
8%
Breast Cancer
100%
Breast Cancer Diagnosis
8%
Breast Cancer Patients
21%
Breast Cancer Risk
6%
Breast Cancer Subtypes
20%
Breast Cancer Survival
8%
Breast Cancer Treatment
8%
Cancer Clinical Trials
8%
Cancer Control
10%
Cancer Stem Cells
8%
Cancer Therapy
8%
Capecitabine
8%
Carcinoma in Situ
8%
CD163
8%
CD4+
6%
Circulating Tumor DNA (ctDNA)
8%
Clinical Trials
11%
Colombia
6%
Confidence Interval
9%
Dexamethasone Treatment
8%
Disease-free Survival
8%
Docetaxel
8%
Early Breast Cancer
15%
EORTC
8%
Esperanza
8%
Estrogen Receptor-positive
8%
Everyday Practices
8%
Gene Expression Profiling
8%
Genetic Epidemiology
8%
Genomic Risk
8%
Glioblastoma
17%
HER2-positive
8%
Hereditary Breast Cancer
8%
Hereditary Ovarian Cancer
8%
HMG-CoA Synthase
6%
Hormone Receptor-negative
6%
Human Epidermal Growth Factor Receptor
8%
Human Epidermal Growth Factor Receptor 2 (HER2)
17%
Immuno-oncology
25%
Indigenous Americans
19%
Integrated Missions
8%
Interobserver Agreement
8%
Intestine
8%
Ketogenesis
8%
Latin American Studies
8%
Latin American Women
8%
Latinas
7%
Letrozole
8%
Liver
8%
LORELEI
8%
Lymphocyte Level
8%
Malignancy
9%
MammaPrint
6%
Metastatic Breast Cancer
8%
Mexico
6%
MicroRNA
8%
MINDACT
8%
Neoadjuvant
10%
Neoadjuvant Chemotherapy
9%
Neoadjuvant Therapy
10%
Newly Diagnosed
8%
Odds Ratio
11%
Oncology Biomarkers
25%
Overall Survival
13%
Pathogenic Variants
8%
Pathologist
11%
Peru
15%
Peruvian
34%
Phase II Trial
16%
PIK3CA
7%
PIK3CA mutation
19%
Pineal Region
8%
Placebo
8%
Placebo-controlled
8%
Postmenopausal Women
8%
Prognostic Factors
9%
Prognostic Implications
8%
Prognostic Information
9%
Programmed Death-ligand 1 (PD-L1)
11%
Radiotherapy
6%
Randomized Double-blind
8%
Regulatory Genes
8%
Residual Cancer Burden
8%
Residual Disease
17%
Risk Management
9%
Risk Management Framework
8%
Stromal Tumor-infiltrating Lymphocytes
19%
Suckling Mice
8%
Taselisib
8%
Triple Negative
12%
Triple-negative Breast Cancer
31%
Tumor
18%
Tumor-infiltrating Immune Cells
16%
Tumor-infiltrating Lymphocytes
66%
Medicine and Dentistry
Biological Marker
34%
Brain Metastasis
8%
Breast Cancer
89%
Cancer
8%
Cancer Control
6%
Cancer Stem Cell
8%
Cancer Therapy
8%
Carcinoma in Situ
8%
Chemotherapy
8%
Circulating Tumor DNA
8%
Clinical Trial
18%
Disease
14%
Estrogen Receptor
9%
Exon
8%
Glioblastoma
9%
Immunocompetent Cell
9%
Immunoglobulin
25%
Letrozole
8%
Malignant Neoplasm
18%
Metastatic Breast Cancer
8%
microRNA
8%
Minimal Residual Disease
18%
Neoadjuvant Chemotherapy
9%
Neoadjuvant Therapy
10%
Neoplasm
27%
Oncology
26%
Pathologist
11%
Placebo
8%
Postmenopause
8%
Prognostic Factor
9%
Programmed Death-Ligand 1
8%
Radiation Therapy
5%
Stromal Tumor
19%
Taselisib
8%
Triple Negative Breast Cancer
31%
Tumor Infiltrating Lymphocyte
74%